Journal: Medicine International
Article Title: The combination of positive anti‑WDR1 antibodies with negative anti‑CFL1 antibodies in serum is a poor prognostic factor for patients with esophageal carcinoma
doi: 10.3892/mi.2023.71
Figure Lengend Snippet: (A) Comparison of s-WDR1-Ab levels between healthy donors and patients with esophageal, gastric, colorectal, lung, and breast cancers examined using an amplified luminescence proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). The s-WDR1-Ab levels are shown in a scatter dot plot. *** P<0.001; NS, not significant. (B) s-WDR1-Ab and s-CFL1-Ab levels using the ROC curve analysis between the alive and deceased cases in 192 patients with esophageal carcinoma. ROC curves for WDR1-Ab and CFL1-Ab are presented. The area under the ROC curve, 95% confidence interval, cut-off levels, specificity and sensitivity, and P-values are presented in . Closed circles indicate the positions with the highest sum of sensitivity plus specificity, i.e., the Youden index. The ROC curve analysis was used to calculate the P-values. WDR1, WD repeat-containing protein 1; CFL1, cofilin 1; s-WDR1-Ab, serum anti-WDR1 antibody; s-CFL1-Ab, serum anti-CFL1 antibody; ROC, receiver operating characteristic.
Article Snippet: AlphaLISA was conducted using 384-well microtiter plates (white opaque OptiPlate™, PerkinElmer, Inc.) containing 2.5 µl 1/100-diluted sera and 2.5 µl GST, GST-WDR1, or GST-CFL1 (10 µg/ml) in AlphaLISA buffer [25 mM HEPES (pH 7.4), 0.1% casein, 0.5% Triton X-100, 1 mg/ml dextran-500 and 0.05% Proclin-300] following the manufacturer's instructions (PerkinElmer, Inc.) and as previously described ( ).
Techniques: Comparison, Amplification
Thermo Fisher is a verified supplier 
Thermo Fisher manufactures this product 
